Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel acquired 3,000 shares of the firm's stock in a transaction on Monday, April 1st. The shares were bought at an average cost of $19.08 per share, with a total value of $57,240.00. Following the completion of the acquisition, the chief executive officer now directly owns 5,350,777 shares in the company, valued at approximately $102,092,825.16. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Snehal Patel also recently made the following trade(s):
- On Friday, March 22nd, Snehal Patel acquired 2,500 shares of Greenwich LifeSciences stock. The shares were bought at an average cost of $19.98 per share, with a total value of $49,950.00.
- On Wednesday, March 20th, Snehal Patel acquired 1,500 shares of Greenwich LifeSciences stock. The shares were bought at an average cost of $17.68 per share, with a total value of $26,520.00.
- On Monday, March 4th, Snehal Patel acquired 4,100 shares of Greenwich LifeSciences stock. The shares were bought at an average cost of $13.03 per share, with a total value of $53,423.00.
- On Thursday, February 15th, Snehal Patel acquired 12,700 shares of Greenwich LifeSciences stock. The shares were bought at an average cost of $11.07 per share, with a total value of $140,589.00.
Greenwich LifeSciences Stock Performance
Urgent dollar warning
From Stansberry Research | Ad
Your 2024 Election Money Blueprint
Voters are angrier than ever, and it's likely to keep getting worse. The media and Wall Street keep declaring how great the economy supposedly is... but no one – besides the ultra-rich – seems to feel that way. Protect yourself with this one simple move today.
Find out for free here.
Shares of NASDAQ GLSI opened at $17.72 on Thursday. Greenwich LifeSciences, Inc. has a twelve month low of $7.58 and a twelve month high of $21.44. The stock's 50 day moving average price is $13.71 and its 200-day moving average price is $11.18.
Hedge Funds Weigh In On Greenwich LifeSciences
Institutional investors have recently bought and sold shares of the company. Bank of America Corp DE lifted its stake in Greenwich LifeSciences by 100.2% in the first quarter. Bank of America Corp DE now owns 6,213 shares of the company's stock valued at $122,000 after purchasing an additional 3,110 shares during the last quarter. Walleye Capital LLC purchased a new position in Greenwich LifeSciences in the second quarter valued at approximately $90,000. Goldman Sachs Group Inc. purchased a new position in Greenwich LifeSciences in the second quarter valued at approximately $104,000. Citigroup Inc. purchased a new position in Greenwich LifeSciences in the first quarter valued at approximately $172,000. Finally, GSA Capital Partners LLP purchased a new position in Greenwich LifeSciences in the fourth quarter valued at approximately $194,000. Hedge funds and other institutional investors own 4.16% of the company's stock.
Analysts Set New Price Targets
Separately, HC Wainwright restated a "buy" rating and issued a $36.00 target price on shares of Greenwich LifeSciences in a research note on Wednesday, February 28th.
Check Out Our Latest Research Report on GLSI
Greenwich LifeSciences Company Profile
(
Get Free Report)
Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
